Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Manzano CL, Sadek A, Cooper C, Tomlinson E, Wang H, Rice C, Tallantyre E, Rao-Middleton A, Whiting P, Thom H.

Open source

DOI: 10.3310/gjht1811
Published: 2026-08-01
Container: Health Technol Assess
Publisher: Not recorded
Open access: no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3310/gjht1811,
  title = {Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.},
  author = {Manzano CL and  Sadek A and  Cooper C and  Tomlinson E and  Wang H and  Rice C and  Tallantyre E and  Rao-Middleton A and  Whiting P and  Thom H.},
  year = {2026},
  journal = {Health Technol Assess},
  doi = {10.3310/gjht1811},
  url = {https://doi.org/10.3310/gjht1811}
}

RIS

TY  - JOUR
TI  - Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.
AU  - Manzano CL
AU  -  Sadek A
AU  -  Cooper C
AU  -  Tomlinson E
AU  -  Wang H
AU  -  Rice C
AU  -  Tallantyre E
AU  -  Rao-Middleton A
AU  -  Whiting P
AU  -  Thom H.
PY  - 2026
JO  - Health Technol Assess
DO  - 10.3310/gjht1811
UR  - https://doi.org/10.3310/gjht1811
ER  -

APA

CL, M., A, S., C, C., E, T., H, W., C, R., E, T., A, R., P, W., & H., T. (2026). Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.. Health Technol Assess. https://doi.org/10.3310/gjht1811

Source records

europe-pmc · retrieved 2026-09-25T00:05:59.077Z
doaj · retrieved 2026-09-25T00:05:59.053Z